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PhosphorylationThe immune system is exquisitely balanced. It has the ability to effectively respond to and control infections
while at the same time preventing inappropriate responses to self and environmental antigens. When this re-
sponse goes awry, either through a failure to activate the immune response, or failure to terminate it, inﬂam-
matory pathology results. Posttranslational modiﬁcations (PTMs) such as ubiquitination and phosphorylation
help ensure that the delicate balance underlying immune signal transduction is maintained. Ubiquitination
and phosphorylation affect localization, activity, stability, and interactions of various components of the im-
mune signal transduction machinery. Moreover, ubiquitination and phosphorylation are tightly linked, with
one PTM affecting the other. Therefore, in order to ﬁnd potential therapies for many immune-related patholo-
gies, it is necessary to understand not only how the immune response is activated by ubiquitination and phos-
phorylation, but also how it is regulated by these PTMs at different stages of the response. An excellent system
to study such activation and regulation is the NOD2 pathway. Dysregulation of NOD2 signaling is involved in
the pathogenesis of a variety of inﬂammatory disorders including Crohn's disease, early onset sarcoidosis, and
Blau syndrome. More recently NOD2 has been implicated in the development of autoimmune disease, allergy
and asthma. This review will focus on what is currently known about how ubiquitination and phosphorylation
regulate NOD2 signaling with particular emphasis on novel in vitro substrates which may serve as potential in
vivo therapeutic targets for hyperactive NOD2 states. This article is part of a Special Issue entitled: Ubiquitin
Drug Discovery and Diagnostics.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
While sequencing of the human genomehas given us the foundation
for cellular processes, post-translational modiﬁcations allow for this
foundation to bemodiﬁed, altered and enriched in response to extracel-
lular cues. Two key post-translational modiﬁcations that affect an array
of proteins are phosphorylation and ubiquitination. During phosphory-
lation, kinases catalyze the transfer of a γ-phosphate group (usually
from ATP) to the nucleophilic centers of acceptor molecules like the
amino acids serine, threonine or tyrosine or to molecules like the phos-
phoinositides. In protein phosphorylation, the phosphorylation event
can lead to a conformational change in the protein that then alters
that protein's activity, localization and/or stability [1]. Alternatively pro-
tein phosphorylation can serve to nucleate binding partners through
phosphorylation-speciﬁc binding domains like SH2 domains [1].
Ubiquitination is equally important, regulating everything from cell
cycle progression and cellular proliferation to antigen processing
and immune signaling. Although initially believed to impart these func-
tions solely through targeting proteins for proteasome-dependent deg-
radation, it is now appreciated that ubiquitination also results in manyDrugDiscovery andDiagnostics.
tt).
l rights reserved.non-degradative functions such as nucleation of signaling complexes, re-
ceptor endocytosis and even modulating kinase activity [2,3].
Given their importance in multiple cellular processes, it is no sur-
prise that there is considerable cross-talk between phosphorylation
and ubiquitination. This interplay can be illustrated through a num-
ber of examples including the SCF E3 ubiquitin ligases in which subs-
trate recognition and degradation are based on the presence of
phosphorylated motifs within target proteins (phosphodegrons) [4]
or the E3 ubiquitin ligase Smurf1 which recognizes GSK phosphoryla-
tion sites on Smad1 to cause Smad1 degradation [5]. This cross-talk
has also recently been recognized to be a major component of both
the activation and deactivation of the NOD2:RIP2 signaling pathway,
a key innate immune pathway with a major role in granulomatous in-
ﬂammatory disease.2. The NOD2 signaling pathway
Nucleotide binding and oligomerization domain 2 (NOD2) is an in-
tracellular protein that senses the presence of muramyl dipeptide
(MDP), a breakdown product of peptidoglycan found in both gram-
negative and gram-positive bacteria [6,7]. Upon recognition of intracel-
lular bacteria, the NOD2 pathway helps direct the secretion of antimi-
crobial peptides, cytokines and chemokines to induce innate immune
Fig. 1. NOD2 and disease. Structure of the NOD2 protein showing location of disease-
associated mutations and polymorphisms with respect to domain organization.
Crohn's disease associated polymorphisms are indicated in boxes with the 3 most com-
monly occurring variants in bold. Blau syndrome mutations are enclosed in circles
above the schematic and early onset sarcoidosis mutations are enclosed in circles
below the schematic.
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tem to help ﬁght the bacterial infection [8]. The NOD2 protein is com-
posed of two N-terminal CARD domains for interacting with other
CARD containing proteins, a central NACHT domain for self-
oligomerization and ten C-terminal leucine-rich repeats (LRRs) that
are thought to be important for the intracellular recognition of MDP
(Fig. 1) [9]. Basally, NOD2 is thought to exist in an autoinhibited state
with the LRRs folded back onto the NACHT domain. Exposure to MDP
causes a conformational change in NOD2 allowing both NOD2 oligo-
merization through the NACHT domain and binding of the dual-
speciﬁcity kinase RIP2 through homotypic CARD–CARD interactions
[10]. Binding to NOD2 promotes RIP2 kinase activation and this active
NOD2:RIP2 complex then activates a number of intracellular signaling
pathways including the MAP Kinase pathways (JNK, ERK, p38), the
NF-κB pathway (Fig. 2A), autophagy and antigen presentation
[8,11–16]. Of these, the best-studied effect of NOD2 activation is its ef-
fect on the transcription factor NF-κB (Fig. 2A).
NF-κB activationmust be tightly regulated to avoid inﬂammatory dis-
ease. Both the activation and the deactivation must be accurately coordi-
nated such that only physiologic, beneﬁcial inﬂammation results.
Upon NOD2:RIP2 activation, RIP2 helps recruit the IKK signalosome
via polyubiquitin networks. RIP2 promotes lysine (K) 63-linked
polyubiquitination of NEMO and RIP2 itself is K63 ubiquitinated
and bound by multiple E3 ligases — cIAP1, cIAP1, XIAP, TRAF2,
TRAF5 and TRAF6 (Fig. 2A) [17–21]. These K63 ubiquitin chains on
bothRIP2 andNEMOpromote recruitment of TAK1by serving as unique
docking sites for TAB2 and TAB3 (TAK1-binding protein 2 and 3) which
have ubiquitin-binding domains [19,22]. Recruitment of TAK1 then
leads to TAK1-mediated phosphorylation and activation of the IKK com-
plex and subsequent activation of NF-κB (Fig. 2A) [23].
Downregulation of NOD2-induced NF-κB signaling is then accom-
plished through recruitment of multiple ubiquitin ligases and ubiquitin-
editing enzymes. TRAF4 is an E3 ligase that has been shown to negatively
regulate NOD2 signaling. Recent data fromour laboratory has shown that
TRAF4 binds directly to NOD2 in an agonist-dependentmanner [24]. This
recruitment brings TRAF4 in proximity such that it can serve as a sub-
strate for IKKα (Marinis et al., in press). IKKα-mediated TRAF4 phosphor-
ylation then allows dissociation of TRAF4 from NOD2 to mediate
inhibition of NOD2 signaling (Fig. 2B). Both TRAF4 binding to NOD2 and
IKKα-mediated TRAF4 phosphorylation are needed for the inhibitory ef-
fect of TRAF4.
RIP2 is also actively downregulated. The HECT E3 ligase ITCH
ubiquitinates RIP2 to downregulate NOD2-induced NF-κB responses
[25]. Here the interplay of phosphorylation and ubiquitination is appar-
ent. Phosphorylation is generally a low stoichiometry event. That is,
signal ampliﬁcation is generated starting from a low basal phosphoryla-
tion statemoving toward a less low phosphorylation state. For instance,
if 0.01% of the total molar amount of protein is basally phosphorylated
and upon activation, 2–5% of the total molar amount becomes phos-
phorylated, this achieves a 200 to 500-fold enrichment in activation.
By extension, if only 5% of a protein is phosphorylated, then enzymes
such as ITCH that help degrade activated RIP2 must have mechanisms
to distinguish activated RIP2 from inactivated RIP2. This distinction is
made via the identiﬁcation of tyrosine phosphorylated RIP2. Upon acti-
vation, RIP2 undergoes autophosphorylation on tyrosine 474 (Y474)
[26]. ITCH recognizes this tyrosine phosphorylated, activated form of
RIP2 to speciﬁcally target activated RIP2 for degradation (Fig. 2B). An
additional level of regulation lies with the protein A20. A20, which
forms a complex with ITCH [27], has both ubiquitin ligase and
ubiquitin-editing capability and is another potent negative regulator of
NOD2 and NF-κB signaling [28,29]. Primary macrophages deﬁcient in
A20 show prolonged NF-κB signaling in response to MDP stimulation
and increased RIP2 ubiquitination [30]. Overexpression of WT but not
the C103AA20mutant (which is defective in its deubiquitinating activity)
reduced RIP2 ubiquitination in overexpression systems [30]. Together,
these suggest that A20's deubiquitinase activity may contribute to thedownregulation of NOD2 responses through deubiquitination of
RIP2 (Fig. 2B). This would represent a similar scenario to that shown
for RIP1, where ITCH-mediated recruitment of A20 is needed for RIP1
deubiquitination and inhibition of NF-κB responses [27].
At the level of IKK complex activation, a number of ubiquitin li-
gases and ubiquitin-editing enzymes are also active. Aside from the
well-documented IKKβ phosphorylation of the NF-κB inhibitor IκBα
to promote its ubiquitination and degradation, our own laboratory
has shown that IKKβ phosphorylates A20 on Ser381 and this phos-
phorylation event is important for inhibition of NF-κB (Fig. 2B) [31]. Re-
cently, there has also been emerging evidence to indicate that A20 can
exert inhibitory effects independent of its deubiquitinase activity.
Skaug et al. have shown that polyubiquitin binding by A20 allows it to
bind NEMO and inhibit IKK phosphorylation by TAK1 (Fig. 2B) [32].
This polyubiquitin binding occurs even in the absence of deubiquitinase
activity. Most likely, A20 employs a combination of these mechanisms
which renders it a very potent negative regulator of NOD2 signaling.
Thus, while much attention has been focused on the NOD2:RIP2's acti-
vation of NF-κB and its role in the coordination of cytokine release,
equally important and perhaps more complicated are the mechanisms
to downregulate NOD2:RIP2 signaling.
3. Disorders of defective NOD2 signaling
3.1. Crohn's disease
NOD2 has gained notoriety as a Crohn's disease susceptibility gene
when, in 2001, three independent laboratories identiﬁed polymorphisms
within NOD2which confer increased risk for developing Crohn's disease,
a type of inﬂammatory bowel disease (IBD) characterized by inﬂamma-
tion in the gastrointestinal tractwhich is transmural, discontinuous and
granulomatous [33–35]. The CD-associated polymorphisms of NOD2
confer a 2–4 fold increased risk if heterozygous and a 20–40 fold in-
creased risk if the individual is homozygous or compound heterozy-
gous. These CD-associated polymorphisms are located within the LRR
region of the protein and are associated with a loss-of-function pheno-
type (Fig. 1, open bold boxes). That is, in vitro stimulation of cells har-
boring these CD-associated variants show loss of NF-κB activation
[6,36]. The ﬁnding that these loss-of-function polymorphisms precipi-
tate inﬂammation seems, at ﬁrst glance, counterintuitive and as such
Fig. 2. Activation and downregulation of NOD2 signaling. A) Exposure to MDP liberates NOD2 from its autoinhibited state allowing it to bind and activate the kinase RIP2. RIP2 un-
dergoes tyrosine autophosphorylation and is ubiquitinated by a number of E3 ligases. RIP2 also promotes ubiquitination of NEMO/IKKγ and by doing so links together proximal and
distal signaling components of the pathway. The TAB proteins of the TAK1/TAB2/TAB3 complex bind these ubiquitin chains allowing TAK1 to phosphorylate and activate the IKK
complex. IKK activation leads to IκBα phosphorylation, marking IκB for degradation and liberating NF-κB for translocation to the nucleus. B) TRAF4 inhibits NOD2 signaling in a
manner dependent on NOD2 binding and IKKα-mediated phosphorylation. The downstream events mediating such inhibition are unknown. A20 is phosphorylated and activated
by IKKβ and together with ITCH, targets activated, tyrosine phosphorylated RIP2 for degradation. In a manner independent of its ubiquitin editing function, A20 also inhibits TAK1-
mediated phosphorylation of IKK.
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unreasonable if viewed as a setting of immunodeﬁciency: where the
failure to respond to a pathogen ultimately leads to increased bacterial
burden and a muchmore severe inﬂammatory response when the bac-
teria are detected through other pathways [37]. Alternatively, other
groups have proposed that the 1007insC polymorphism actually ex-
hibits a gain-of-function phenotype to actively repress IL-10 transcrip-
tion, thereby allowing excessive inﬂammation [38]. While this ﬁnding
is supported by the fact that IL-10 levels are decreased in cells from pa-
tients harboring the 1007insC polymorphism, the low penetrance of
Crohn's disease in peoplewith one or two Crohn's disease susceptibility
alleles and the general autosomal recessive inheritance pattern suggests
against a gain-of-function phenotype. This central paradox of NOD2 ge-
netics elicits a number of potential explanations. However, to date, the
exact mechanisms explaining the disparity between the effects of the
loss-of-function polymorphisms on downstream NOD2 signaling and
the pathology observed, have yet to be fully elucidated.
Although NOD2 polymorphisms are the most frequently altered
defect in genetic CD, the majority of patients who develop Crohn's
disease actually have wild-type NOD2. It is not unlikely, therefore,
that in these cases the defect might lie in other components of the
NOD2 signaling pathway which are faulty in either the propagationor the termination of this innate immune response. Additionally, as
NOD2 and RIP2 are both NF-κB regulated genes, upon inﬂammatory
stimulation, both NOD2 and RIP2 expression increase dramatically
[39]. It has been postulated that inhibition of NOD2:RIP2 signaling
in the background of WT NOD2 may be efﬁcacious in Crohn's disease
[40,41]. It appears that the mucosal immune system lies in such a deli-
cate immunologic homeostasis that any perturbation, either positively
or negatively, may result in inﬂammation.
3.2. Early onset sarcoidosis and Blau syndrome
What is intriguing about the genetics of NOD2, is that a separate
set of mutations all occurring within the NACHT domain result in a
different type of granulomatous disease — early onset sarcoidosis
(EOS) and Blau syndrome (Fig. 1, open circles) [42,43]. The EOS and
Blau syndrome mutations, unlike the CD-associated polymorphisms,
are autosomal dominant, gain-of-functionmutations that are associated
with over-activation of the NOD2 pathway as evidenced by increased
basal NF-κB activity even in the absence of agonist [43,44]. EOS and
Blau syndrome are characterized by the triad of skin, joint and eye in-
ﬂammation and are thought to be the sporadic and familial forms of
the same genetic disease [43,45]. The late-onset and adult forms of
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and enlargement of the hilar lymph nodes [46,47]. A recent study de-
scribed what may be additional variants of NOD2 hyperactive disorders
(so-called autoinﬂammatory NOD2 disorders) characterized by periodic
fever, dermatitis, and polyarthritis [48]. A subset of these patients har-
bors one of the gain-of-function autosomal dominant mutations
(R702W), while all were positive for the NOD2 IVS8 +158 mutation
[48].Whether this represents a distinct intronicmutation or is amarker
for a co-segregating unidentiﬁed gain-of-functionmutation, is yet to be
discovered. Thus, as seenwith both Crohn's disease and early onset sar-
coidosis, any perturbation of NOD2, either positive or negative, can lead
to granulomatous inﬂammatory disease.
3.3. Allergy and asthma
NOD2 has also been implicated in the development of allergic re-
sponses. Two independent genetic analyses of large German cohorts
have found that some polymorphisms within NOD2 are associated
with increased total serum IgE levels, atopic dermatitis, and atopic
rhinitis but that other polymorphisms and haplotypes seem to be pro-
tective for these traits [49,50]. In a separate study looking at Canadian
and Australian populations, there was an association between NOD2
polymorphisms and airway hyperresponsiveness [51]. Studies in mice
using the NOD2 agonist, MDP, similarly implicate NOD2 as being in-
volved in the generation of Th2 immunity and the development of asth-
matic and allergic responses. Immunization of mice using ovalbumin
withMDP as an adjuvant showed increased secretion of Th2 related cy-
tokines and elevation of antigen-speciﬁc IgG1 antibodies [52]. Other
studies by the same group show that direct administration of MDP dur-
ing intranasal tolerization protocols block respiratory tolerance and
promote susceptibility to asthmatic disease [53]. NOD2 signaling in
both stromal cells and DCs were determined to be crucial for develop-
ment of optimal Th2 responses [54]. These studies are highly suggestive
of overactive NOD2 signaling as a contributor to allergic and asthmatic
disease.
3.4. Other autoimmune diseases
There is also emerging evidence for the involvement of NOD2 in
autoimmune disease. Genetic analysis of NOD2 in individuals withmul-
tiple sclerosis (MS) and systemic lupus erythematosus (SLE) shows an
increased susceptibility of developing SLE in individuals with harboring
the 908R polymorphism [55]. Interestingly, occurrence of this polymor-
phism is also increased in a subset of IBD patients with spondylarthritis
[56,57]. Although initial studies of psoriatic arthritis have suggested an
increase in the occurrence of this disease in patients harboring loss-of-
function polymorphisms in NOD2, more recent studies have not been
able to replicate these associations [58–61].
The connection between NOD2 and autoimmunity was further
strengthened by the ﬁnding that stimulation of human dendritic cells
with the NOD2 agonist MDP in combination with other TLR agonists
(especially TLR2), promotes the development of T helper 17 (Th17)
cells through the induction of IL-23 and IL-1 [62]. Th17 cells are a subset
of T cells that secrete proinﬂammatory cytokines (most notably IL-17)
and have been shown to be important in the control of certain bacterial
infections but have also implicated in the pathogenesis of various auto-
immune conditions [63]. Studies using genetically deﬁcient mice also
support the involvement of the NOD2 pathway. By subjecting mice to
experimental autoimmune encephalomyelitis (EAE), a mouse model
of MS, the authors show that mice deﬁcient in NOD2 or RIP2 are more
resistant to development of EAE [64]. Defective autoantigen-speciﬁc T
cell development and expansion were not responsible for these results.
Instead, a defect in RIP2 signaling in CNS-inﬁltrating dendritic cells
(DCs) was suggested to drive the autoimmune pathology [64]. As with
all studies using mouse models, it will be important to verify theseﬁndings in patient samples and through the use of human genetics. To
date, however, there is no human genetic linkage of NOD2 to MS.
3.5. ITCH-deﬁciency
Not surprisingly, genetic loss of a potent negative regulator of the
NOD2 signaling pathway, the E3 ubiquitin ligase ITCH, results in wide-
spread inﬂammation in various mucosal compartments — the skin,
the lungs and the intestinal tract [65]. The majority of patients found
to be deﬁcient in ITCH (harboring a truncation mutation rendering
them essentially null) present with chronic lung disease, highlighting
this as a major organ of involvement by ITCH and by proxy, NOD2
[66]. Our laboratory has shown that bone marrow-derived macro-
phages from ITCH-deﬁcient mice (itchy) have increased basal and
MDP-inducible NOD2 responses [25]. Furthermore, if we subject this
genetically-susceptible strain of mice to a mouse sarcoidosis model
(intraperitoneal immunization and intratracheal challenge with heat-
killed Propionibacterium acnes), we are able to observe a much more
pronounced granulomatous inﬂammatory lung response in the itchy
mice compared to their wild-type counterparts (Tigno-Aranjuez et al.,
unpublished results). Therefore, ITCH-deﬁciency represents a unique set-
ting of NOD2 overactivation, one where NOD2 status is genetically wild-
type but where loss of negative regulation still precipitates disease.
Although loss-of-function CD-associated polymorphisms of NOD2
are most famous for being implicated in genetic Crohn's disease, there
are now multiple examples of NOD2 overactivation causing inﬂamma-
tory disease (Table 1). These now include: EOS, Blau syndrome, autoin-
ﬂammatory NOD2 disorders, allergy and asthma, EAE, systemic lupus
erythematosus, and ITCH-deﬁciency. Given that hyperactive NOD2:
RIP2 signaling is implicated in the pathophysiology of these disorders
when NOD2 is WT, in this genetic background, patients might beneﬁt
from pharmacologic downregulation of NOD2 signaling.
4. Novel NOD2 pathway inhibitors
Until recently, it was believed that the kinase activity of RIP2was dis-
pensable for downstream activation of the NOD2 pathway. This conclu-
sion was based on in vitro overexpression studies using kinase-dead
versions of RIP2 which showed an equal or greater ability to activate
NF-κB compared towild-type RIP2 [12,67]. However,more recent stud-
ies have begun to question these conclusions. One study using a kinase-
dead (K47A) knock-in mouse showed that RIP2's kinase activity was
important for its expression [68]. A second study using an inhibitor of
both RIP2 and p38 showed that the kinase activity of RIP2 was impor-
tant for both RIP2 expression and for MDP-induced cytokine responses
[69]. These, as well as our own observations, led us to more formally in-
terrogate the importance of RIP2's kinase domain in the activation of
the NOD2 pathway. RIP2 was originally classiﬁed as a serine/threonine
kinase [11,70]. However, no RIP2 substrates had been clearly identiﬁed
which could be used as potential targets or markers of activation of the
NOD2 pathway. Previous use of RIP2 itself as a potential marker of
NOD2 activation has also met with limited success as an anti-phospho
Ser176 RIP2 antibody, which, although speciﬁc [71], does not seem to
detect MDP-inducible phosphorylation of RIP2 (Abbott Laboratory,
unpublished results).
Although RIP2 was originally described as a serine–threonine ki-
nase, we have recently found that RIP2 is actually a dual-speciﬁcity
kinase, capable of phosphorylating not only serines and threonines
but tyrosines as well [26]. Our laboratory has demonstrated that RIP2
is not only a bona ﬁde tyrosine kinase through in vitro kinase assays,
but has shown that RIP2 is inducibly tyrosine autophosphorylated at ty-
rosine 474 (Y474) in response to NOD2 activation [26]. This ﬁnding
opened up new avenues for identifying potential inhibitors of the
NOD2 pathway. Using a small molecule tyrosine kinase inhibitor screen,
we discovered two additional FDA-approved drugs— Tarceva (Erlotinib)
and Iressa (Geﬁtinib), which are capable of inhibiting RIP2 tyrosine
Table 1
How NOD2 inﬂuences inﬂammatory disease.
Disease Way in which NOD2 inﬂuences disease
Crohn's disease Negatively: loss-of-function polymorphisms cause
inﬂammatory granulomatous disease
Early onset sarcoidosis/
Blau syndrome
Positively: gain-of-function mutations cause inﬂamma-
tory granulomatous disease
Allergy and asthma Positively: the NOD2 agonist MDP promotes Th2
immunity when used as an adjuvant; MDP administra-
tion during tolerization protocols blocks respiratory
tolerance
Autoimmunity Positively: increased susceptibility of developing SLE in
patients with the 908R polymorphism; in murine
models, NOD2 or RIP2 deﬁcient mice showed more
resistance to development of EAE
ITCH deﬁciency Positively: loss of ITCH, a key negative regulator of NOD2
signaling, causes exacerbation of what should be normal
NOD2 signaling
2026 J.T. Tigno-Aranjuez, D.W. Abbott / Biochimica et Biophysica Acta 1823 (2012) 2022–2028activity in the nanomolar range [26]. We showed that these drugs can
inhibit downstreamMDP-induced cytokine responses and are effective,
at least in vitro, in alleviating the exacerbated cytokine responses in
NOD2 hyperactive states such as in primary macrophages which lack
ITCH, or in macrophage cell lines overexpressing the Blau syndrome-
associated mutation R334Q [26]. Whether these drugs can also inhibit
these inﬂammatory states in vivo still remains to be tested. It would
also be interesting to determine whether lung cancer patients who
have been receiving or who had received Tarceva and Iressa show
symptoms correlating with modulation of NOD2 signaling.
Tarceva and Iressa were designed as inhibitors of EGFR, a receptor
tyrosine kinase, and are usedmost commonly for treatment of lung can-
cers [72]. These drugs work as competitive inhibitors of ATP by binding
to the ATP-binding pocket of their target kinase. Because the RIP2-
inhibitory effect of Tarceva and Iressa was found as an off-target effect
of these drugs, caution must be used in applying these inhibitors in
situations where EGFR signaling may be important. Although we have
shown that Tarceva and Iressa are speciﬁc for RIP2 relative to EGFR in
macrophages,we cannot rule out the possibility that there are additional
off-target effects of these agents. For this reason, and given that RIP2 re-
mains an attractive pharmacologic target in inﬂammatory disease, it will
be important to develop speciﬁc RIP2 antagonists.
Additionally, a number of ubiquitin ligases have been associated with
a positive inﬂuence on the NOD2 signaling pathway (cIAP1, cIAP2, XIAP)Table 2
Drugs which inhibit NOD2 signaling.
Drug Manufacturer Target NOD2 pathway
off-target
Mode of action
AT-406 Ascenta
Therapeutics
IAPs Orally active Sm
cIAP2; promotes
degradation
TL-32711 TetraLogic
Pharmaceuticals
IAPs Smac mimetic
LBW242, LCL161 Novartis IAPs Smac mimetic
GDC-0152, GDC-0917 Genentech IAPs Smac mimetic
AEG35156,
AEG40826-2HCl
Aegera XIAP XIAP antisense o
SB 203580 GlaxoSmithKline P38 RIP2 Competitive inh
SB 203580
SB 220025
PD 169316
GlaxoSmithKline P38 RIP2 Competitive inh
Iressa (Geﬁtinib),
Tarceva (Erlotinib)
AstraZeneca,
Genentech
EGFR RIP2 Competitive inh
Arene–Cr(CO)3 complexes
such as AKS-01
University of
Cologne
NOD2 NOD2 Proposed compe[20,21]. Numerous pharmacological inhibitors for these ligases are avail-
able and are currently at various stages of clinical trials (Table 2). Al-
though originally designed for inhibition of IAPs in association with
cancer, it is possible that the same inhibitors could be repurposed for
the downregulation of NOD2 signaling as well, albeit in a less-speciﬁc
manner than NOD2 or RIP2 inhibitors. As of the writing of this review,
there has been successful development of selective and potent NOD1
inhibitors which show inhibition of NOD1-mediated activation of NF-
κB and NF-κB mediated cytokine responses [73–75]. The same studies
which screened and tested for NOD1 inhibitors also led to the identiﬁca-
tion of NOD2 speciﬁc inhibitors. However, the structural, chemical, and
functional information for the compounds which resulted from this
screen have yet to be published. There is one report which describes
arene chromium-complexes (AKS-01 being the most potent) as speciﬁc
inhibitors of NOD2-mediated NF-κB signaling [76,77]. These compounds
seem to be active in a variety of cell lines (HEK 293, THP, primarymurine
DCs) and show no effects on reduction of NF-κB signaling mediated
through other pathways such as TNFα, TLR2 and TLR4 and only a slight
reduction in NOD1-mediated NF-κB signaling [76,77]. However, as with
the Erlotinib and Geﬁtinib, further studies are needed to determine in
vivo efﬁcacy and safety.5. Potential avenues for research
There are stillmanyunanswered questions regardingNOD2 signaling.
For example, although RIP2 undergoes inducible tyrosine autophosphor-
ylation in response to MDP stimulation, the other downstream targets of
RIP2 kinase activity have yet to be discovered. Can these be exploited for
clinical gain? Second, RIP2 is modiﬁed bymultiple ubiquitin ligases. How
is this affecting its kinase activity and if so, how is this modulation
achieved? Does regulation between the different ubiquitin ligases
occur? Is this affected by RIP2 kinase activity? Third, we have mentioned
numerous ubiquitin ligases and the substrates involved in the modula-
tion of NOD2 signaling. If we understood the exact nature of ubiquitin li-
gase substrate recognition in these cases, would it be feasible to design
small molecule inhibitors (decoys) to disrupt the complexes which are
formed speciﬁcally in NOD2 signaling? What are the other NOD2
pathway-speciﬁc substrates for these ligases (for example, no substrates
have been described for TRAF4)? Fourth, it is clear that dysregulated
NOD2 signaling results in a variety of disorders. What molecular events
are common among certain disease states? Can these be used as diagnos-
tic markers and utilized in a personalized approach to treatment?Phase Reference
ac mimetic; binds to the BIR3 regions of XIAP, cIAP1 and
caspase-9 activation for XIAP and promotes cIAP1
I [78]
II [79]
Preclinical,
I
[80]
I [79]
ligonucleotide I/II
I
[81]
ibitor of ATP binding Preclinical [82]
ibitor of ATP binding Preclinical [83]
ibitor of ATP binding FDA
approved
[26]
titive inhibitor of MDP Preclinical [76, 77]
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will probably be needed to answer many of these questions, movement
toward a systems biology approach to understanding NOD2 signaling is
most likely in order. The downstreameffects ofNOD2 and RIP2 activation
outside of NF-κB are still not clearly delineated. Although it is well docu-
mented that engagement of NOD2 activates the MAPK pathways, the
exact mechanism of how this occurs is still unknown. It is also well
known in the ﬁeld that MDP is a very weak agonist, at least compared
to other ligands for TLRs. Are we missing something crucial in down-
stream NOD2-mediated effects? Furthermore, there is clearly cross-
talk between the different microbe associated pattern receptors. For in-
stance, NOD2 has repeatedly been associatedwith a number of antiviral
recognition receptors and pathways [84,85]. How is RIP2 kinase activity
affecting activation of these pathways and which ubiquitin ligases and
substrates are recruited to mediate speciﬁc antiviral responses? The
vast developments in the ﬁelds of genetics and the decrease in the
costs for sequencing analysis open up new avenues for further advance-
ment of the NOD2 ﬁeld. For example, one could employ whole exome
sequencing to identify new and rare mutations or polymorphisms in
NOD2 itself or in components of the NOD2 pathway. One level above
studying the genetic differences which underlie many of the aforemen-
tioned diseases is the study of epigenetic changeswhich occur inNOD2-
associated disorders. ChIP-Seq can be used to determine not only pro-
tein–DNA interaction events speciﬁc to NOD2 activation but DNA
methylation and histone modiﬁcation events as well. RNA sequencing
technology now offers greater advantages from traditional microarray
technology, removing the bias of focusing on only selected known ge-
netic sequences (hybrid-based technology) but also allowing quantita-
tion of expression levels especially for very low or very high mRNA
expression. In addition, RNA-seq allows one to determine differential
splicing patterns and RNA-editing events. These technologies combined
with the appropriate questions, proper controls, and relevant study de-
sign, are bound to yield valuable information to further our current un-
derstanding of NOD2 signaling and provide insight on howwemight be
able to arrive at targeted therapies for NOD2-related disorders.
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